About The Rx Consultant

The Rx Consultant is a subscription-based service that delivers practical updates & reviews covering all the top-selling drugs and common health conditions. Our publications focus on the facts busy front-line pharmacists and other health care practitioners need to stay current, and provide it a streamlined, easy reading style.

Founded in 1991, The Rx Consultant has subscribers throughout the United States, Canada & The United Kingdom. For 27 years, pharmacists, nurse practitioners and pharmacy technicians have relied on The Rx Consultant for accurate, unbiased updates they can trust. We are completely independent of the pharmaceutical industry and has no commercial bias.

→ Visit The Rx Consultant

Rx Blog users - Save 40% on a subscription to
The Rx Consultant

Use Promo Code RXBLOG18

→ Subscribe Now

Researchers performed chart review among 500 adult patients discharged from an emergency department (ED) with new prescriptions to investigate potential interactions with preexisting medications. Patient’s reported home medications and the newly prescribed medications by the ED provider were analyzed using the Lexicomp electronic drug interaction checker. Thirty eight percent of the patients had at least 1 drug interaction. Of the 429 interactions identified, 67 (15.6%) were classified as requiring no intervention, 260 (60%) as requiring therapeutic monitoring, 95 (22%) needed modification of therapy, and 7 (1.6%) were classified as avoid combinaion. Oxycodone/acetaminophen, ibuprofen, ciprofloxacin, prednisone and albuterol were the most common drugs implicated. A limitation of the study is that it was not known if patients actually filled the prescriptions. This study suggests that ED providers may not be considering potential drug interactions when prescribing medications. Be extra vigilant in screening for drug interactions when presented with prescriptions from ED providers.

• Jawaro T. et al. Am J Emer Med https://doi.org/10.1016/j.ajem.2019.01.049

Subscribe To Our Newsletter

Join our mailing list to receive the latest news and updates from our team.

You have Successfully Subscribed!

Share This